Early interventional treatment with intranasal mometasone furoate in Japanese cedar/cypress pollinosis: A randomized placebo-controlled trial

Seiichiro Makihara, Mitsuhiro Okano, Tazuko Fujiwara, Masayo Kimura, Takaya Higaki, Takenori Haruna, Yohei Noda, Kengo Kanai, Shin Kariya, Kazunori Nishizaki

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Background: Little is known about the safety and effectiveness of early interventional treatment (EIT) with intranasal corticosteroids for seasonal allergic rhinitis. We designed a double-blinded, randomized, placebocontrolled 12-week trial of EIT with mometasone furoate nasal spray (MFNS) for Japanese cedar/cypress pollinosis (JCCP). Methods: A total of 50 JCCP patients received MFNS (200 μg once daily: n = 25) or placebo (n = 25) starting on February 1, 2010. Treatments continued until the end of April. The primary endpoint was the comparison of the total nasal symptom score (TNSS) between the MFNS and placebo groups. The secondary endpoints included comparisons of QOL, daytime sleepiness, nasal ECP levels, and safety. Results: Continuous dispersion of Japanese cedar pollen began on February 22. Although the placebo group showed a significant worsening of symptoms after the start of the continuous dispersion, no worsening occurred in the MFNS group. A significant difference in the TNSS between the two groups was seen starting at 4 weeks after the treatment. Similar results were seen for QOL and sleepiness. Nasal ECP levels in March were significantly lower in the MFNS group. A total of 56% of the MFNS group progressed to a persistent allergic rhinitis state in accordance with the ARIA classification, as opposed to 84% of the placebo group. MFNS was well tolerated, and the plasma cortisol concentrations were similar between the two groups. Conclusions: EIT with MFNS for JCCP is both safe and effective. This treatment can potentially lessen symptoms and help pollinosis patients remain in the intermittent state.

Original languageEnglish
Pages (from-to)295-304
Number of pages10
JournalAllergology International
Volume61
Issue number2
DOIs
Publication statusPublished - 2012

Fingerprint

Mometasone Furoate
Cupressus
Cryptomeria
Nasal Sprays
Seasonal Allergic Rhinitis
Randomized Controlled Trials
Placebos
Nose
Therapeutics
Safety
Pollen

Keywords

  • Early interventional treatment
  • ECP
  • Intranasal corticosteroids
  • Japanese cedar/cypress pollinosis
  • Total nasal symptom score

ASJC Scopus subject areas

  • Immunology and Allergy

Cite this

Early interventional treatment with intranasal mometasone furoate in Japanese cedar/cypress pollinosis : A randomized placebo-controlled trial. / Makihara, Seiichiro; Okano, Mitsuhiro; Fujiwara, Tazuko; Kimura, Masayo; Higaki, Takaya; Haruna, Takenori; Noda, Yohei; Kanai, Kengo; Kariya, Shin; Nishizaki, Kazunori.

In: Allergology International, Vol. 61, No. 2, 2012, p. 295-304.

Research output: Contribution to journalArticle

@article{27f32fdfd0174d91955402414b86971d,
title = "Early interventional treatment with intranasal mometasone furoate in Japanese cedar/cypress pollinosis: A randomized placebo-controlled trial",
abstract = "Background: Little is known about the safety and effectiveness of early interventional treatment (EIT) with intranasal corticosteroids for seasonal allergic rhinitis. We designed a double-blinded, randomized, placebocontrolled 12-week trial of EIT with mometasone furoate nasal spray (MFNS) for Japanese cedar/cypress pollinosis (JCCP). Methods: A total of 50 JCCP patients received MFNS (200 μg once daily: n = 25) or placebo (n = 25) starting on February 1, 2010. Treatments continued until the end of April. The primary endpoint was the comparison of the total nasal symptom score (TNSS) between the MFNS and placebo groups. The secondary endpoints included comparisons of QOL, daytime sleepiness, nasal ECP levels, and safety. Results: Continuous dispersion of Japanese cedar pollen began on February 22. Although the placebo group showed a significant worsening of symptoms after the start of the continuous dispersion, no worsening occurred in the MFNS group. A significant difference in the TNSS between the two groups was seen starting at 4 weeks after the treatment. Similar results were seen for QOL and sleepiness. Nasal ECP levels in March were significantly lower in the MFNS group. A total of 56{\%} of the MFNS group progressed to a persistent allergic rhinitis state in accordance with the ARIA classification, as opposed to 84{\%} of the placebo group. MFNS was well tolerated, and the plasma cortisol concentrations were similar between the two groups. Conclusions: EIT with MFNS for JCCP is both safe and effective. This treatment can potentially lessen symptoms and help pollinosis patients remain in the intermittent state.",
keywords = "Early interventional treatment, ECP, Intranasal corticosteroids, Japanese cedar/cypress pollinosis, Total nasal symptom score",
author = "Seiichiro Makihara and Mitsuhiro Okano and Tazuko Fujiwara and Masayo Kimura and Takaya Higaki and Takenori Haruna and Yohei Noda and Kengo Kanai and Shin Kariya and Kazunori Nishizaki",
year = "2012",
doi = "10.2332/allergolint.11-OA-0382",
language = "English",
volume = "61",
pages = "295--304",
journal = "Allergology International",
issn = "1323-8930",
publisher = "Japanese Society of Allergology",
number = "2",

}

TY - JOUR

T1 - Early interventional treatment with intranasal mometasone furoate in Japanese cedar/cypress pollinosis

T2 - A randomized placebo-controlled trial

AU - Makihara, Seiichiro

AU - Okano, Mitsuhiro

AU - Fujiwara, Tazuko

AU - Kimura, Masayo

AU - Higaki, Takaya

AU - Haruna, Takenori

AU - Noda, Yohei

AU - Kanai, Kengo

AU - Kariya, Shin

AU - Nishizaki, Kazunori

PY - 2012

Y1 - 2012

N2 - Background: Little is known about the safety and effectiveness of early interventional treatment (EIT) with intranasal corticosteroids for seasonal allergic rhinitis. We designed a double-blinded, randomized, placebocontrolled 12-week trial of EIT with mometasone furoate nasal spray (MFNS) for Japanese cedar/cypress pollinosis (JCCP). Methods: A total of 50 JCCP patients received MFNS (200 μg once daily: n = 25) or placebo (n = 25) starting on February 1, 2010. Treatments continued until the end of April. The primary endpoint was the comparison of the total nasal symptom score (TNSS) between the MFNS and placebo groups. The secondary endpoints included comparisons of QOL, daytime sleepiness, nasal ECP levels, and safety. Results: Continuous dispersion of Japanese cedar pollen began on February 22. Although the placebo group showed a significant worsening of symptoms after the start of the continuous dispersion, no worsening occurred in the MFNS group. A significant difference in the TNSS between the two groups was seen starting at 4 weeks after the treatment. Similar results were seen for QOL and sleepiness. Nasal ECP levels in March were significantly lower in the MFNS group. A total of 56% of the MFNS group progressed to a persistent allergic rhinitis state in accordance with the ARIA classification, as opposed to 84% of the placebo group. MFNS was well tolerated, and the plasma cortisol concentrations were similar between the two groups. Conclusions: EIT with MFNS for JCCP is both safe and effective. This treatment can potentially lessen symptoms and help pollinosis patients remain in the intermittent state.

AB - Background: Little is known about the safety and effectiveness of early interventional treatment (EIT) with intranasal corticosteroids for seasonal allergic rhinitis. We designed a double-blinded, randomized, placebocontrolled 12-week trial of EIT with mometasone furoate nasal spray (MFNS) for Japanese cedar/cypress pollinosis (JCCP). Methods: A total of 50 JCCP patients received MFNS (200 μg once daily: n = 25) or placebo (n = 25) starting on February 1, 2010. Treatments continued until the end of April. The primary endpoint was the comparison of the total nasal symptom score (TNSS) between the MFNS and placebo groups. The secondary endpoints included comparisons of QOL, daytime sleepiness, nasal ECP levels, and safety. Results: Continuous dispersion of Japanese cedar pollen began on February 22. Although the placebo group showed a significant worsening of symptoms after the start of the continuous dispersion, no worsening occurred in the MFNS group. A significant difference in the TNSS between the two groups was seen starting at 4 weeks after the treatment. Similar results were seen for QOL and sleepiness. Nasal ECP levels in March were significantly lower in the MFNS group. A total of 56% of the MFNS group progressed to a persistent allergic rhinitis state in accordance with the ARIA classification, as opposed to 84% of the placebo group. MFNS was well tolerated, and the plasma cortisol concentrations were similar between the two groups. Conclusions: EIT with MFNS for JCCP is both safe and effective. This treatment can potentially lessen symptoms and help pollinosis patients remain in the intermittent state.

KW - Early interventional treatment

KW - ECP

KW - Intranasal corticosteroids

KW - Japanese cedar/cypress pollinosis

KW - Total nasal symptom score

UR - http://www.scopus.com/inward/record.url?scp=84862661960&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862661960&partnerID=8YFLogxK

U2 - 10.2332/allergolint.11-OA-0382

DO - 10.2332/allergolint.11-OA-0382

M3 - Article

C2 - 22441634

AN - SCOPUS:84862661960

VL - 61

SP - 295

EP - 304

JO - Allergology International

JF - Allergology International

SN - 1323-8930

IS - 2

ER -